Introduction
Acute coronary syndrome (ACS) represents a spectrum of ischemic heart disease that includes ST-segment elevation myocardial infarction (STEMI), non-ST-segment elevation myocardial infarction (NSTEMI), and unstable angina (UA). Although ischemic heart disease continues to remain the leading cause of mortality worldwide [1] , the frequency of type of ACS has changed over the past two decades, making non-ST-segment elevation acute coronary syndrome (NSTE-ACS) (NSTEMI and UA) the most prevalent type of ACS in contemporary practice [2, 3] . Although the most recent practice guidelines from the American College of Cardiology and the American Heart Association (AHA) for NSTE-ACS recommend early invasive management and the provisional use of revascularization for patients who are acceptable candidates, the literature on the specific role of coronary artery bypass graft surgery (CABG) for NSTE-ACS has not been comprehensively summarized nor analyzed [4] . We therefore reviewed the considerations of utilizing CABG for patients who present with NSTE-ACS.
Utilization of CABG for NSTE-ACS
Following presentation with NSTE-ACS, only a small proportion of patients eventually undergo CABG during their index ACS hospitalization after a series of steps. As highlighted in Fig. 1 , two decisions are required for an NSTE-ACS patient to undergo CABG. First, a cardiologist decides whether the patient is an appropriate candidate for angiography. Following initial angiography, the angiographic findings and the patient's clinical characteristics are evaluatedboth factor into the second decision relating to the use and type of revascularization procedure: CABG or percutaneous coronary intervention (PCI). These decisions play a role in the type and timing of therapies provided to the patient (Fig. 2) . A previous publication from the Acute Coronary Treatment and Intervention Outcomes Network Registry -Get With The Guidelines, a registry of the National Cardiovascular Data Registry, reported that 11.5% of patients presenting with NSTEMI in 2009 underwent CABG compared with 43.6% of patients who underwent PCI (whereas 76.2% underwent angiography) [5] . Over the next few years, the use of angiography for NSTEMI patients in the Acute Coronary Treatment and Intervention Outcomes Network Registry increased slightly, whereas CABG was consistently performed in ∼ 11% of patients [6] (Fig. 3) .
Although it appears that the utilization of CABG for the overall NSTEMI population has remained relatively constant in contemporary practice, the proper patient denominator to use to assess the ultimate utilization of CABG remains uncertain. For example, among elderly NSTEMI patients included in the previous Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes With Early Implementation of the ACC/AHA Guidelines trial who were found to have significant coronary disease on angiography, 18.2% underwent CABG within 30 days of their index event [7] . In addition, among NSTEMI patients included in the Acute Coronary Treatment and Intervention Outcomes Network Registry in 2012 who did not have previous CABG and who were found to have three-vessel or left main coronary disease during angiography, ∼ 40% underwent CABG, 40% underwent PCI, and 20% did not undergo revascularization ( Fig. 4) . Thus, utilization rates of CABG for NSTEMI can vary widely on the basis of the target population being analyzed and perceived indications for CABG ( Fig. 5 ).
Factors influencing the decision to perform CABG for NSTEMI
Although revascularization has superior outcomes compared with medical management alone for NSTE-ACS patients, the decision on the type of revascularization (CABG vs. PCI) is individualized on the basis of patient characteristics and technical features [4] . However, certain factors favor one method of revascularization over the other for these patients.
The key anatomic considerations that favor CABG are significant left main or three-vessel coronary artery disease, or significant two-vessel coronary disease with ostial or proximal left anterior descending artery stenosis [9] . The most recent NSTE-ACS practice guidelines provide similar anatomic recommendations to support the use of CABG for patients found to have significant coronary disease during angiography [10] . Although anatomic Decision tree for patients who present with NSTE-ACS. For patients who present with NSTE-ACS, two decision points exist for them to receive CABG. angio, angiography; CABG, coronary artery bypass graft surgery; cath, catheterization; D1, first decision on whether to pursue angiography; D2, second decision on revascularization method; MM, medical management; NSTE-ACS, non-ST-segment elevation acute coronary syndrome; PCI, percutaneous coronary intervention; revasc, revascularization. Summary of antiplatelet medication and anticoagulation management after presentation with NSTE-ACS. Careful management of antiplatelet medications and anticoagulation is imperative after a patient presents with NSTE-ACS. Prompt initiation of DAPT and anticoagulation after the diagnosis is made. If the decision is to proceed with angiography, these medications are continued. (a) If the decision is to proceed with CABG, anticoagulation is continued and DAPT is discontinued until surgery. DAPT is then restarted before discharge. (b) If the decision is to proceed with PCI, anticoagulation is discontinued after intervention. DAPT is continued through discharge. (c, d) If noninvasive management or no revascularization is pursued, then anticoagulation is discontinued during the hospitalization. DAPT is continued through discharge. angio, angiography; ASA, aspirin; CABG, coronary artery bypass graft surgery; cath, left-heart catheterization; DAPT, dual antiplatelet therapy; NSTE-ACS, non-ST-segment elevation acute coronary syndrome; PCI, percutaneous coronary intervention; P2Y12, P2Y12 inhibitor; revasc, revascularization.
considerations from the angiographic findings likely are the key decision-making point for the use of CABG versus PCI for NSTE-ACS patients, a recent publication reported that the use of PCI was associated with a statistically higher risk of major adverse cardiac events (death, myocardial infarction, or target lesion revascularization) through 1 year compared with CABG among patients with NSTEMI [11] . These findings likely relate to residual confounding in terms of the decision to perform PCI versus CABG, but suggest that CABG may be preferentially selected for NSTE-ACS patients with a lower expected long-term risk.
The SYNTAX trial randomized patients with stable ischemic heart disease who had unprotected left main or three-vessel disease to CABG or PCI [12] . The SYNTAX score, used in the trial to quantify the extent of coronary artery disease in a patient, is another tool that has been used to help determine patients with NSTE-ACS who may benefit from CABG as opposed to PCI. The latest follow-up of the SYNTAX trial suggests that patients with a SYNTAX score greater than 22 would benefit from CABG as opposed to PCI, although these data are not from patients with NSTE-ACS [13, 14] .
In addition to these anatomic considerations, certain key subgroups deserve further evaluation. [16, 17] . In addition, the FREEDOM trial that randomized diabetic patients who had multivessel disease to PCI or CABG showed a survival advantage for the CABG cohort [18] . Given the association of DM with both chronic kidney disease and a greater burden of atherosclerosis, CABG should be preferred for NSTE-ACS patients with either DM or chronic kidney disease to ensure more complete and durable revascularization [4, 19] . Finally, the use of CABG versus PCI for women with NSTE-ACS is confounded by the known smaller diameter coronary arteries of women versus men and by the older age of women versus men at the time of presentation with NSTE-ACS [5] . Therefore, it remains uncertain what the best type of revascularization strategy should be for female patients with NSTE-ACS who do have multivessel coronary disease. Although referring to the revascularization appropriate use guidelines for delineation between CABG versus PCI is beneficial in providing a reference point, these guidelines were formulated for patients with stable ischemic heart disease (Table 1) . For patients with NSTE-ACS, the goal of adequate revascularization should be an even higher priority, given the unstable nature of NSTE-ACS and the potential for threatened myocardium. Despite the increased risk of stroke associated with CABG compared with PCI overall [20] , this difference is reduced if not eliminated in patients with NSTE-ACS [7] . For these reasons, CABG may be preferred over PCI, given its ability to provide a more adequate revascularization, although further research is needed to clearly establish the appropriate management of these patients.
Although randomized trials comparing CABG with PCI specifically for NSTE-ACS patients have not been conducted, two trials published in 2001 compared CABG versus PCI and included patients with UA. The Arterial Revascularization Therapy Study, which included patients with UA, had a total of 1205 patients randomized to CABG versus PCI, but did not show a difference in the rate of death, stroke, or myocardial infarction through 1 year, although the incidence of repeat revascularization was higher in the PCI cohort [21] . In addition, a randomized trial from Argentina included 450 patients, 92% of whom had UA, randomized to CABG and PCI, and showed a small increase in survival with PCI, although this trial had a higher perioperative mortality rate than reported elsewhere in the literature at the time [22] . Given the advancement of technology for both CABG and PCI procedures since those trials were conducted more than 15 years ago, these results are difficult to relate to current-day practice.
Notwithstanding guideline recommendations and clinical evidence, decisions on the method of revascularization for NSTE-ACS patients with multivessel coronary disease should be individualized to the patient and the clinical situation. A consistent recommendation in the more recent revascularization guidelines is the use of a Heart Team in clinical decision making [9, 23] . This multidisciplinary decision-making approach originated from the SYNTAX trial, which required eligible patients to be evaluated by an interventional cardiologist and a cardiac surgeon [12] . Although not supported by data [24] , an integrated, multidisciplinary decision-making approach involving both cardiologists and cardiac surgeons may be the preferred approach, but is not used widely in practice currently in the USA.
Preoperative considerations
After deciding on CABG for NSTE-ACS patients, the next decision is the timing of the procedure. Multiple studies have indicated that an early invasive management strategy with prompt coronary angiography and provisional use of revascularization for patients with NSTE-ACS is associated with better outcomes compared with an early conservative management strategy [25] [26] [27] . However, the optimal timing of subsequent CABG for NSTE-ACS patients, following identification of multivessel coronary disease during angiography, remains uncertain.
In terms of the timing of CABG for NSTE-ACS, studies are conflicting. Two observational studies from 2010 both reported equivalent in-hospital mortality and 30-day mortality rates irrespective of the timing of CABG from admission for NSTE-ACS [28, 29] . A more recent study by Davierwala et al. [30] analyzed 750 patients over a Kaplan-Meier curves showing long-term mortality cumulative incidence from 30 days after hospital discharge through 5 years for patients stratified by treatment group: medical management versus percutaneous coronary intervention (PCI) versus coronary artery bypass grafting (CABG) -P < 0.0001 for three-way comparisons among groups. Reproduced with permission [7] . 5-year period and showed similar in-hospital mortality and 5-year mortality rates among NSTE-ACS patients who underwent CABG in less than 24, 24-72 h, versus more than 72 h after symptom onset. However, NSTE-ACS practice guidelines highlight certain conditions that should prompt urgent revascularization including cardiogenic shock, refractory ischemia despite optimal medical therapy, sustained ventricular arrhythmias, or dynamic ST-segment changes accompanying ischemic symptoms [4] .
In addition to delineating the optimal timing of CABG for NSTE-ACS patients, the coordination of preoperative medications is important. Guideline-recommended acute (< 24 h) medications for NSTE-ACS include antiplatelet agents and anticoagulants as well as other medications such as β-blockers and statins. Because most antithrombotic medications are started acutely as soon as NSTE-ACS is diagnosed, perioperative decisions mainly focus on when and whether to stop particular medications before surgery, attempting to balance the risk of rethrombosis with the risk of increased bleeding during or after CABG.
NSTE-ACS practice guidelines recommend the use of dual antiplatelet therapy (aspirin plus an oral P2Y12 inhibitor) for the acute and discharge treatment of all patients as shown in Fig. 2 . Aspirin is typically started as soon as possible for patients without contraindications and is commonly continued during and after CABG without major concerns about bleeding risks [4, 23] . Although NSTE-ACS guidelines recommend the upstream use of a P2Y12 inhibitor for the acute (< 24 h) treatment of NSTE-ACS irrespective of the intended revascularization strategy, not all patients are receiving early P2Y12 inhibitor therapy in accordance with guideline recommendations. A recent analysis of the Acute Coronary Treatment and Intervention Outcomes Network Registry -Get With The Guidelines showed that only 57% of NSTEMI patients are receiving a P2Y12 inhibitor within 24 h in current US practice [31] . Clopidogrel, prasugrel, and ticagrelor are commonly used P2Y12 inhibitors with different bleeding risks as well as different pharmacokinetic and pharmacodynamic profiles for drug offset following discontinuation [32, 33] . Current guidelines recommend that prasugrel should be discontinued for at least 7 days before elective CABG to decrease CABG-related major bleeding risks compared with at least 5 days of discontinuation for clopidogrel and ticagrelor [9] . A paper by Hansson et al. [34] supplies new evidence that waiting for 5 days may not be necessary. In this analysis, they show that waiting 3 days as opposed to 5 days did not increase the rate of CABG-related major bleeding for patients on ticagrelor. The necessary waiting periods for drug offset before CABG may drive the inclination to withhold the loading dose of a P2Y12 inhibitor until after identification of the coronary anatomy with early coronary angiography, but treatment pathways vary considerably across US hospitals in the preferred timing of the start of P2Y12 inhibitors. More precise decision making for the timing of CABG following discontinuation of a P2Y12 inhibitor may be supported by serial platelet function testing to identify the threshold for recovery of platelet function to prompt CABG (on the basis of diminished concerns about bleeding risk), but no large, prospective studies have been completed as yet to reliably test this strategy [35] . Our institutional experience is to treat patients with a P2Y12 inhibitor upstream of angiography. If the postprocedural plan is for CABG, the P2Y12 inhibitor is discontinued and the patient undergoes surgery 4-5 days after angiography irrespective of the P2Y12 inhibitor that was used. In the time between angiography and surgery, the patient is anticoagulated with unfractionated heparin (UFH) or bivalirudin if there is a contraindication to heparin (Fig. 2) . Our institutional practice is to start/restart dual antiplatelet therapy after surgery.
The management of anticoagulation is less complicated because of the shorter half-lives of these parenteral/subcutaneous medications compared with oral P2Y12 inhibitors. UFH, enoxaparin, bivalirudin, and fondaparinux are the medications recommended for anticoagulation after NSTE-ACS presentation, although UFH is predominantly used in the USA [6] . These medications can usually be discontinued between 6 and 24 h before CABG depending on the particular medication and UFH is restarted during initiation of cardiopulmonary bypass.
Although the data for a relationship between the preoperative use of β blockers and perioperative mortality rates are controversial, the role of perioperative and postoperative β-blockers in this setting for reducing the risk of postoperative atrial fibrillation has been established [36, 37] . Current CABG guidelines recommend the continuation of β-blocker medications in the perioperative setting for patients who are on a β-blocker preoperatively [9] .
Statin therapy is also important in the perioperative setting. In addition to cholesterol-lowering properties, statins are increasingly being recognized as a useful antiinflammatory adjunct for cardiac surgery patients [38] [39] [40] . Current guidelines recommend the early initiation and continuation of high-intensity statin therapy after NSTE-ACS and continuation in the perioperative setting with a goal of an LDL-C less than 100 mg/dl with further titration to 70 mg/dl if possible [4, 9, 10, 23] . A previous cohort study by Collard et al. [41] reported that preoperative statin was associated with reduced cardiac mortality, whereas discontinuation postoperatively was associated with increased in-hospital mortality.
Postoperative considerations
Medication management in the postoperative setting following CABG for NSTE-ACS is more straightforward.
The reduction in mortality associated with aspirin following CABG is well established and it should be continued without interruption [42] . The role of P2Y12 inhibitor therapy after CABG in patients with NSTE-ACS is more controversial. Although NSTE-ACS guidelines are clear in recommending dual antiplatelet therapy (aspirin plus a P2Y12 inhibitor) for 12 months for all patients irrespective of the in-hospital use and type of revascularization procedure on the basis of consistent results across patient groups in the pivotal trials for the currently used P2Y12 inhibitors [4, 23] , the 2011 American College of Cardiology Foundation/AHA Guidelines for CABG do not specifically recommend P2Y12 inhibitors after CABG for NSTE-ACS patients [9] . Although a small, underpowered trial of dual antiplatelet therapy versus aspirin after elective CABG showed no difference in saphenous vein graft intimal hyperplasia, the role of dual antiplatelet therapy after CABG is currently still being investigated [43, 44] .
Angiotension converting enzyme inhibitors or angiotensin receptor blockers are also indicated after CABG for NSTE-ACS, especially for patients with DM and those with left ventricular systolic dysfunction [4] . These medications should either be reinitiated or added after CABG. Long-term outcomes are improved in patients on angiotension converting enzyme inhibitors or angiotensin receptor blockers following CABG [45] , although there are less adverse events when starting 7 days or greater after surgery [46] .
Postoperative statins and β-blocker should be administered as soon as possible following CABG for NSTE-ACS. The long-term mortality benefit associated with statin therapy [41, 47] and the benefit in prevention of postoperative atrial fibrillation associated with β-blocker therapy [36, 37] have been discussed already. Data further suggest that postoperative β-blocker use is associated with decreased long-term mortality after CABG [48] .
Conclusion
Although only a minority of NSTE-ACS patients undergo CABG as a definitive treatment for their index ACS event, there are many complex decision-making steps following hospital presentation that occur before the decision to perform CABG is confirmed. The timing of CABG for NSTE-ACS is strongly influenced by the upstream use of oral P2Y12 inhibitors (which need to be discontinued for 5-7 days after angiography to allow for recovery of platelet function before CABG) and is individualized on the basis of patient clinical characteristics. Therefore, integrated decision making with cardiologists and cardiac surgeons is needed to optimize the concomitant medical treatments and the preoperative, perioperative, and postoperative outcomes for NSTE-ACS patients who undergo CABG.
